Clinical Trials Directory

Trials / Completed

CompletedNCT02468570

A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302

A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, 165-302

Status
Completed
Phase
Study type
Observational
Enrollment
9 (actual)
Sponsor
BioMarin Pharmaceutical · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

A Phase 3 substudy to evaluate executive function in adults with phenylketonuria who are participating in the phase 3 Study, 165-302. Approximately 100 subjects, aged ≥ 18 to ≤ 70 years old, with PKU will be enrolled.

Detailed description

Study 165-303, is a Phase 3 substudy enrolling approximately 100 subjects, aged ≥ 18 to ≤ 70 years old, with PKU who are participating in the Phase 3 study, 165-302. Per the 165-303 protocol, the investigator does not assign a specific intervention to the study participants. In accordance with the protocol for Study 165-303, subjects were asked to perform selected set of three tasks from the CANTAB tool (Rapid Visual Processing \[RVP\], Spatial Working Memory \[SWM\], and Stop Signal Task \[SST\]) to assess executive function and each subject's self perception of their current state was measured using a subject global assessment questionnaire that contains seven questions about current state perception of attention, energy level, tiredness, confusion, sadness, anger and tension. The time points for administering the above tools are as follows, which coincide with time points in part 2 and part 4 of Study 165-302: screening (entry into Part 2 165-302 Day 1 of Week 1), baseline visit (Part 2 Week 8), and 3 additional study visits at different time points in the Part 4 of 165-302 study.

Conditions

Interventions

TypeNameDescription
OTHERAdministration of CANTAB and Subject Global AssessmentAt designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire

Timeline

Start date
2015-08-05
Primary completion
2017-02-01
Completion
2017-02-01
First posted
2015-06-11
Last updated
2020-06-04
Results posted
2020-06-04

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02468570. Inclusion in this directory is not an endorsement.